Pigment Epithelium-Derived Factor Promotes the Growth and Migration of Human Esophageal Squamous Cell Carcinoma

De-Rong Tang, Cheng-Lin Li, Ke-Ping Xu, Qing-Quan Wu, Qi-You Chen, Jun-Jie Lv, Jian Ji, Bao Zang, Chen Chen, Biao Gu and Jian-Qiang Zhao*

Department of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China

Pigment epithelium-derived factor (PEDF) is an oncogene found in various types of cancers. However, how PEDF affects the development of human esophageal squamous cell carcinoma (ESCC) is unknown. This study investigates the role of PEDF in ESCC cell proliferation, migration, and cell cycle both in vitro and in vivo. The PEDF expression was examined in patient tumor samples and ESCC cell lines. Short hairpin RNA technology was used to inhibit the PEDF expression in ESCC EC9706 and KYSE150 cells. In vitro cell proliferation and migration assays were performed. The effects of PEDF on tumor growth and progression were examined in vivo in murine subcutaneous xenograft tumor models. It was found that PEDF was overexpressed in esophageal cancer cells and patient tumor tissues compared to normal control samples. PEDF enhanced cell cycle progression and inhibited cell apoptosis. Knock down of PEDF inhibited esophageal cell proliferation and migration in vitro. Moreover, inhibition of PEDF significantly reduced tumor growth and tumor size in vivo. These results indicate that PEDF induce tumorigenesis in ESCC and can be a potential therapeutic target for cancer treatment.

Keywords: pigment epithelium-derived factor (PEDF), esophageal carcinoma, tumorigenesis, proliferation, migration

INTRODUCTION

Esophageal carcinoma is a common gastrointestinal cancer that has two major subtypes: adenocarcinoma and squamous cell carcinoma (1). It is the sixth cancer-related deaths worldwide. There were about 16,940 newly diagnosed cases of esophageal carcinoma in the United States (accounting for 1% of all new-onset cancer cases) and 15,690 deaths (accounting for 2.6% of all cancer-related deaths) in 2016 (2). The incidence of esophageal squamous cell carcinoma (ESCC) is very high in some areas of China. There are ~5,500 confirmed cases of disease in 5 million people each year in Huai’an city, the northern part of Jiangsu Province, China. Although progress has been made in the diagnosis and treatment of esophageal carcinoma, its 5-year survival rate is still dismal (1). Therefore, it is imperative to further explore the molecular basis of esophageal carcinoma and develop more effective treatment strategy.

Pigment epithelium-derived factor (PEDF), a member of the serine protease inhibitor superfamily, was initially isolated from the retinal pigment epithelial cells of human fetus (3). PEDF has neuroprotective and anti-angiogenic activity (4). PEDF is highly expressed in adipose tissue, liver, eye, heart, skeletal muscle, spleen, brain, and bone (5–10). PEDF plays significant biological
roles in many physiological and pathophysiological processes, including neuroprotection, fibrosis and inflammation (11). Previous studies have shown that PEDF plays important roles in cancer angiogenesis, tumor growth and metastasis (12, 13). Therefore, the potential use of PEDF as a target in the treatment of cancer has attracted much attention. However, the mechanisms of PEDF in cancer development remain controversial. PEDF shows antitumour effect in some tumors, including pancreatic, melanoma, and ovarian cancers (14–16). On the other hand, the level of PEDF is higher than that of normal tissues in some other cancers. For example, PEDF can promote stem cell growth and self-renewal of glioma stem cells (17, 18). PEDF was also found in hepatocellular carcinoma cells where PEDF levels were higher in HCC cases than in normal paracancerous tissues. The secretion of PEDF was higher in HCC patients than in normal controls, suggesting the potential of using serum PEDF as a biomarker for hepatocellular carcinoma (19). Therefore, the function of PEDF and its mechanism of action in various cancers need to be further investigated before it can be used as a biomarker for diagnosis and prognosis, or for cancer treatment.

In this study, we found that PEDF is overexpressed in tissues and cells of esophageal carcinoma. In addition, we observed that PEDF promotes esophageal cancer cell growth both in vivo and in vitro. This study will provide a rational for using PEDF as a prognostic biomarker and a potential therapeutic target for esophageal carcinoma.

MATERIALS AND METHODS

Tissue Samples
A total of 40 cases of esophageal cancer patients admitted to the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University were enrolled in this study. Tumor and corresponding normal tissues were obtained. None of the patients received any radiation or chemotherapy before surgery. Surgical specimens were immediately frozen in liquid nitrogen and stored at −80°C for proteins assays. This study was carried out with the approval of the Ethics Committee of the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University. A written informed consent was obtained from each patient.

Cell Lines and Cell Culture
Human esophageal cancer cell lines (EC9706, KYSE150) were purchased from Shanghai Cell Bank of Chinese Academy of Sciences. The cells were cultured in RPMI-1640 medium (Invitrogen, USA) containing 10% heat inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and 1% penicillin / streptomycin in an incubator with 5% CO₂ at 37°C.

Cell Transfection
The short hairpin RNA was used to knockdown PEDF (shPEDF, 5'-AGCGAACAGATCCATTCTTC-3', shPEDF1, 5'-GAACGATCTATCATCATT-3', shPEDF2, 5'-TGTTCGATTCGAGACTT-3', Invitrogen, USA). Cells were transfected with pL3.7-shPEDF, and 5 ug of packaging viral plasmid using Lipofectamine 2000 (Invitrogen).

Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-PCR) Assay
Total RNA was extracted from tissues and cells using Trizol reagent (Invitrogen) according to the manufacturer’s instructions. One microgram of RNA was then reversely transcribed into cDNA using M-MLV reverse transcriptase (Invitrogen). PEDF mRNA expression was detected using an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems) using a fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA), with β-actin as an endogenous control. The primer sequences for PEDF and β-actin are as follows: PEDF, 5'-ACT GAG TAA GAT GGC GGG TCG-3' (forward) and 5'-TTC TGG CGA AAG CGG GTA G-3' (reverse); and 5'-AAA TCG GTG ACA TCA AAG A-3' (forward) and 5'-GGC CAT CTC CTG GAA-3' (reverse).

Western Blot Analysis
Total protein was extracted from cells and patients’ tissues using RIPA buffer (Beyotime, Shanghai, China) containing a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) and quantified using the Pierce™ BCA Protein Assay Kit (Invitrogen; Thermo Scientific). The same amount of protein (50 µg) was then separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose filter (NC membrane; Millipore, Billerica, MA, USA). Membranes were then blocked in 5% skim milk for 1 h at room temperature and blocked with primary antibodies against PEDF(ab10389), caspase 3(ab197202), caspase 9(ab219590) (Abcam, Cambridge, Mass., USA), overnight at 4°C followed by incubation with horseradish peroxidase (HRP) conjugated goat anti-rabbit secondary antibody (ab6721, 1:1,000, Abcam) for 1 h at room temperature. Finally, specific protein signals were visualized using ECL Western blotting substrates (Promega, Madison, WI, USA) and quantified by Image J software (National Institutes of Health, Bethesda, Maryland, USA).

Transwell Invasion Assay
Invasion chambers (BD Bioscience, San Diego, Calif., USA) were used to assess cell invasiveness using a membrane with a pore size of 8 µm (BD Bioscience). Briefly, EC9076 and EC109 cells infected with shRNA were resuspended in serum-free RPMI-1640 medium (100 µl) and inoculated in 40 µl of Matrigel (BD Biosciences) with 700 µl RPMI-1640 medium and 10% FBS. After incubation at 37°C for 48 h, cells on the upper side of the membrane were removed with a sterile swab. The cells on the lower side of the membrane were fixed with methanol for 30 min, stained with 0.1% crystal violet for 20 min, and counted in six randomly selected fields at 200 X magnification using an inverted microscope (Nikon Eclipse TE300, Tokyo, Japan).

Flow Cytometry for Cell Cycle and Apoptosis Analysis
Cell cycle was determined according to the manufacturer’s protocol with propidium iodide (PI) staining (Nanjing Kaji Biotechnology Development Co. Ltd., Nanjing, China). Briefly,
EC9076 and EC109 cells were transfected with shRNA. The cells were then harvested and resuspended in 500 μl 1X binding buffer at a concentration of 1 × 10⁶ cells / ml, followed by the addition of 5 μl of PI. The treated cells were then incubated for 5 min at room temperature in the dark. Finally, the cell cycle and apoptotic rate of the cells was analyzed using a FACS Calibur flow cytometer (Beckman Coulter, Atlanta, GA, USA).

**In vivo Experiments**

BALB/c nude mice (6–7 weeks old, male) were obtained from Chinese Academy of Sciences (Shanghai, China) and grown under specific pathogen-free conditions. All animal studies are conducted in accordance with the University Laboratory Animal Management, and approved by the Ethics Committee of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University. To investigate the knock down effect of PEDF on tumor growth in vivo, stably transfected EC9706 cells were subcutaneously injected into the ventral region of nude mice at a concentration of 1 × 10⁷ cells / ml. According to the formula of 0.5 × L × W², the tumor volume was measured every 3 days with a caliper. On day 24 after injection, tumors from all mice were obtained, weighed, and fixed in formalin.

**Statistical Analysis**

All data from three independent experiments were obtained and expressed as mean ± SD. Student’s t-test or one-way ANOVA was used to analyze differences between different groups. The difference was considered statistically significant when P <0.05.

**RESULTS**

**PEDF Is Overexpressed in Esophageal Squamous Cell Carcinoma**

To investigate the role of PEDF in ESCC, we compared the expression of PEDF in ESCC and adjacent normal tissues in 40 patients. Our results showed that the protein expression of PEDF in tumor samples is significantly higher than that in their corresponding normal tissues in those 40 patients (Figure 1A). These results indicated that PEDF is associated with the development of ESCC.

**PEDF Enhances Cell Proliferation and Migration in Esophageal Squamous Cell Carcinoma**

Because PEDF is overexpressed in esophageal carcinoma, we explored the role of PEDF in esophageal carcinoma by knocking down the expression of PEDF in two esophageal carcinoma cell lines EC9706 and KYSE150. In order to determine the best knock-down efficiency, we synthesized three shRNA. The results showed that shRNA-PEDF markedly suppressed the expression of PEDF proteins and mRNA (Figure 1B). Therefore, shRNA-PEDF was used in the following assays. Colony formation assay was used to determine the cell growth after knocking down PEDF expression.
PEDF. The result showed significant reduction of the colony numbers of esophageal carcinoma cells at 7 days after transfection of shRNA (Figure 2A).

The effect of cell migration after knocking down PEDF in esophageal carcinoma cells was also investigated. The transwell assay revealed that shRNA-PEDF significantly attenuated cell migration. 

![Figure 2](image)

**FIGURE 2** | Effect of PEDF knockdown on anchorage-independent growth of esophageal cancer cells. (A) Colony formation assay, and (B) invasion assay, of esophageal cancer cells after knocking down PEDF. * < 0.05.

![Figure 3](image)

**FIGURE 3** | Effect of PEDF knockdown on cell cycle and apoptosis of esophageal cancer cells. (A) Cell cycle change of esophageal cancer cells after knocking down PEDF. (B) Apoptosis assay of esophageal cancer cells after knocking down PEDF. (C) Western blot analysis of apoptosis-related proteins after knocking down PEDF in esophageal cancer cells. * < 0.05, ** < 0.01.
FIGURE 4 | Xenografts with or without PEDF knock down in nude mice. (A) Tumor size at the end time point. (B) Tumor volume over all time points. (C) Tumor weight at the end time point. * < 0.05.
migration compared to control group. There were less esophageal carcinoma cells migrated in shRNA-PEDF transfection group than those in control group. This result indicated that PEDF promote esophageal carcinoma cell migration (Figure 2B). The above results suggested that suppression of PEDF could reduce proliferation and migration of esophageal carcinoma cells.

**PEDF Promotes Cell Cycle and Reduces Cell Apoptosis in Esophageal Squamous Cell Carcinoma**

Because PEDF enhances esophageal carcinoma cell growth, we further investigated whether PEDF affects cell cycle and cell apoptosis. To explore the cell cycle change after shRNA transfection, esophageal carcinoma cells were stained with propidium iodide (PI) and analyzed by Flow cytometry. As expected, knocking down PEDF increased cells in G0/G1 phase and decreased cells in S phase and G2/M phase compared to shRNA scramble group (Figure 3A).

Flow cytometry was used to determine cell apoptosis after shRNA transfection and Annexin-V/PI staining. The result demonstrated that knocking down PEDF increased early apoptotic cells, late apoptotic cells, and necrotic cells (Figure 3B), suggesting that knocking down PEDF increased apoptosis of esophageal carcinoma cells. Furthermore, Western blot shows that the levels of caspase 3 and caspase 9 in the shRNA-PEDF group were higher than in control group (Figure 3C).

**PEDF Promotes Tumourigenesis of Esophageal Squamous Cell Carcinoma in vivo**

To further test the effect of PEDF in esophageal carcinoma cell growth in vivo, we establish xenograft mouse models. Nude mice were injected with EC9706 cells transfected with shRNA control or shRNA-PEDF. Similar to in vitro results, the tumor volume and tumor weight of xenografts in mice inoculated with shRNA-PEDF cells were smaller than that with shRNA control cells, suggesting that PEDF promotes esophageal carcinoma growth in vivo (Figures 4A–C).

**DISCUSSION**

PEDF is a 50 kDa secreted protein which is a versatile member of the widely expressed serpin family, also denoted as SERPINF1 (1). It plays important roles in angiogenesis, fibrogenesis, neuroprotection, bone matrix mineralization, and inflammation (4). Although PEDF was firstly identified as being produced by retinal pigment epithelial cells, it is now known to express in a variety of tissues and cell types, including chondrocytes, and synovial cells. PEDF is naturally present in serum (20, 21). In addition to the many beneficial effects that PEDF possesses, it is involved in the pathogenesis of diseases, such as chronic inflammatory diseases, atherosclerosis, type 2 diabetes, and some types of brain tumors (22, 23). Moreover, PEDF protects osteoblasts from glucocorticoid-induced apoptosis, and increases vascular permeability of triglycerides by ATGL degradation (24). Anti-inflammatory and antithrombotic effects of PEDF have been reported, and PEDF can also prevent the adhesion and invasion of liver cancer cells (25).

PEDF is associated with signaling pathways related to cancer development. PEDF can directly bind to PEDF receptor (PEDFR) and stimulate the activity of phospholipase (26). PEDFR is strongly linked to cell proliferation in cancers (27). Moreover, PEDF has an effect on cancer cell migration by activating MKK3 and MKK6. Tumor cell apoptosis is also regulated by PEDF acting on PPAR and NF-kB (28, 29). On the other hand, PEDF is a key regulatory factor in endothelial cells. Angiogenesis is inhibited by PEDF via cleaving VEGFR1 and VEGFR2 at the transmembrane region and VEGF-induced phosphorylation (30).

In this study, we demonstrate that PEDF is overexpressed in esophageal cancer tissues and cells compared to normal human counterparts. These results are consistent with studies of other cancers, such as prostate cancer (31). Previous studies have shown that the abnormal expression of PEDF is closely related to the pathological process of tumor development, including proliferation, migration, invasion, and apoptosis (32). shRNA-mediated knockdown of PEDF was reported to be effective in inhibiting the growth of melanoma (33). We investigated the impact of knockdown of PEDF on the progression of esophageal cancer in vitro and in vivo. The results showed that shRNA-mediated reduction of PEDF significantly inhibited the proliferation and invasion of esophageal cancer cells and induced apoptosis. In vivo experiments further confirmed that shRNA-mediated PEDF knockdown significantly blocked xenograft esophageal tumor growth. Our results demonstrated that PEDF plays a role in the development of esophageal cancer. However, there was a report shown that PEDF may have potent antiangiogenic and antitumor effects in ESCC cells naturally not secreting endogenous PEDF, in the cell line secreting endogenous PEDF, there is no inhibition of angiogenesis and no subsequent antitumor properties (34).

Taken together, our study showed that PEDF expression is significantly increased in esophageal cancer tissues and cells. Knockdown of PEDF significantly inhibited esophageal cancer cell proliferation and tumourigenesis both in vitro and in vivo. Therefore, PEDF may serve as a prognostic biomarker and potential therapeutic target for esophageal cancer.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/supplementary material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Ethics committee of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University.
AUTHOR CONTRIBUTIONS

D-RT performed experiments and drafted the manuscript. CL-L carried out the cell culture. K-PX participated in the design. Q-QW, Q-YC, and J-JL collected tissue specimens. J-J carried out the Western blot analysis. BZ participated in Transwell invasion study. BG processed specimens. J-QZ conceived the study, coordination, and edited the manuscript. All authors read and approved the study.

REFERENCES

1. Zhu L, Zhang X, Fu X, Li Z, Sun Z, Wu J, et al. TIPE2 suppresses progression and tumourigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway. J Transl Med. (2018) 16:7. doi: 10.1186/s12976-018-1383-0
2. Chen S, Zhou K, Yang L, Ding G, Li H. Racial differences in esophageal squamous cell carcinoma: incidence and molecular features. Biomed Res Int. (2017) 2017:1204082. doi: 10.1155/2017/1204082
3. Ohno-Matsu K, Yoshida T, Uetama T, Mochizuki M, Morita L. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun. (2003) 303:962–7. doi: 10.1016/S0006-291X(03)00446-7
4. Bouck N. PEDF: anti-angiogenic guardian of ocular function. J Transl Med. (2018) 16:e84016. doi: 10.1371/journal.pone.0084016
5. Zhou Y, Xu F, Deng H, Bi Y, Sun W, Zhao Y, et al. PEDF expression is inhibited by insulin treatment in adipose tissue via suppressing IGF-1/HS1. PLoS ONE. (2013) e84016. doi: 10.1371/journal.pone.0084016
6. Moreno-Navarrete JM, Touskova V, Sabater M, Mraz M, Drapalova J, Ortega F, et al. Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance. Int J Obes. (2013) 37:1230–7. doi: 10.1038/ijob.2012.223
7. Yang S, Luo T, Zhou H, Lv Q, Liu L, Zhang W, et al. Rosiglitazone inhibits PEDF messenger RNA ratio of the inner edge of rat hepatocellular carcinoma induced by diethyl nitrosamine - an in vivo study. Hepatogastroenterology. (2012) 59:1484–90. doi: 10.5754/hge11543
8. Tahara N, Matsu S, Yamagishi S. Change in serum PEDF level after pioglitazone treatment is independently correlated with that in HOMA-IR. Int J Cardiol. (2014) 172:244–6. doi: 10.1016/j.ijcard.2013.12.289
9. Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Cancerogenesis. (2013) 34:1265–72. doi: 10.1093/carcin/bg3056
10. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsu T, Inoue H. Serum levels of pigment epithelium-derived factor. (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev. (2009) 25:53–6. doi: 10.1002/dmr.820
11. Yamagishi S, Nakamura K, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor. (PEDF) prevents diabetes- or advanced glycation end products. (AGE)-induced retinal leukostasis. Microvasc Res. (2006) 72:86–90. doi: 10.1016/j.mvr.2006.04.002
12. Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun. (2004) 316:573–9. doi: 10.1016/j.bbrc.2004.02.076
13. Yoshida T, Yamagishi S, Nakamura K, Matsu T, Imaizumi M, Takeuchi T, MatsuM1. Pigment epithelium-derived factor. (PEDF) inhibits advanced glycation end product. (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. Dig Dis Sci. (2017) 62:1527–36. doi: 10.1007/s10620-017-4550-x
14. Filleur S, Yamagishi S, Nakamura K, Imaizumi T, Takeuchi M, Kuroda S, et al. Administration of pigment epithelium-derived factor. (PEDF) inhibits cold-induced brain edema in mice. Brain Res. (2007) 1167:92–100. doi: 10.1016/j.brainres.2007.04.088
15. Sanagi T, Yabe T, Yamada H. Gene transfer of PEDF attenuates ischemic brain damage in the rat middle cerebral artery occlusion model. J Neurochem. (2008) 106:1841–54. doi: 10.1111/j.1471-4159.2008.05529.x
16. Yoshida T, Akiba J, Matsu T, Nakamura K, Hisamato T, Abe M, et al. Pigment epithelium-derived factor. (PEDF) Prevents hepatic fat storage, inflammation, and fibrosis in diabetic rats. Biochim Biophys Acta. (2013) 1831:1226–33. doi: 10.1016/j.bbadis.2013.04.010
17. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Down-regulation of PEDF expression by ribozyme transgene in endothelial and lung cancer cells and its impact on angiogenesis in vitro. Oncol Rep. (2005) 14:1615–9. doi: 10.3892/or.14.6.1615
18. Chen Y, Cazelles R, Wala N, Cruzat VE, Keane K, John AN, et al. Pigment epithelium-derived factor. (PEDF) regulates metabolism and insulin secretion from a clonal rat pancreatic beta cell line BRIN-BD11 and mouse islets. Mol Cell Endocrinol. (2016) 426:50–60. doi: 10.1016/j.mce.2016.02.004
19. Fernandez-Barral A, Orzgl J, Gomez V, del Peso L, Calzada MJ, Jimenez B, et al. Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism. PLoS ONE. (2012) 7:e32989. doi: 10.1371/journal.pone.0032989
20. Sahin N, Apaydin N, Töz E, Sivrikoz ON, Genç M, Turan GA, et al. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch Gynecol Obstet. (2016) 293:1101–6. doi: 10.1007/s00404-015-3987-4
21. Yin J, Park G, Kim TH, Hong HJ, Kim YJ, Jin X, et al. Correction: pigment epithelium-derived factor. (PEDF) expression induced by EGFR/PI3K promotes self-renewal and tumour progression of glioma stem cells. PLoS Biol. (2016) 14:e1002367. doi: 10.1371/journal.pbio.1002367
22. Yin J, Park G, Kim TH, Hong HJ, Kim YJ, Jin X, et al. Pigment epithelium-derived factor. (PEDF) expression induced by EGFR/PI3K promotes self-renewal and tumour progression of glioma stem cells. PLoS Biol. (2015) 13:e1002152. doi: 10.1371/journal.pbio.1002152
23. Jeng KS, Sheen IS, Jeng WJ, Su JC. PEDF effectively decreases VEGF to PEDF messenger RNA ratio of the inner edge of rat hepatocellular carcinoma induced by diethyl nitrosamine - an in vivo study. Hepatogastroenterology. (2012) 59:1484–90. doi: 10.5754/hge11543
24. Martinez-Marin D, Jarvis C, Nelius T, de Riese W, Volpert OV, Filleur S. PEDF increases the tumouricidal activity of macrophages towards prostate cancer cells in vitro. PLoS ONE. (2017) 12:e0174968. doi: 10.1371/journal.pone.0174968
32. Chen X, Li C, He T, Mao J, Li C, Lyu J, et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumour growth through upregulation of PEDF expression. *Cancer Biol Ther.* (2016) 17:507–14. doi: 10.1080/15384047.2016.1156273

33. Zand S, Buzney E, Duncan LM, Dadras SS. Heterogeneity of metastatic melanoma: correlation of MITF with its transcriptional targets MLSN1, PEDE, HMB-45, and MART-1. *Am J Clin Pathol.* (2016) 146:353–60. doi: 10.1093/ajcp/aqw115

34. Kadoya M, Tamoto E, Shichinohe T, Hirano S. Pigment epithelium-derived factor inhibits the growth of human esophageal squamous cell carcinoma by suppressing neovascularization. *Hokkaido J Med Sci.* (2015) 90:17–29.

**Conflicts of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tang, Li, Xu, Wu, Chen, Lv, Ji, Zang, Chen, Gu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.